This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wan, X. S. Articles by Kennedy, A. R. Search for Related Content PubMed PubMed Citation Articles by Wan, X. S. Articles by Kennedy, A. R.

Relationship between Protease Activity and neu Oncogene Expression in Patients with Oral Leukoplakia Treated with the Bowman Birk Inhibitor¹

Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 [X. S. W., A. R. K.], and Departments of Medicine [T. H. T., F. L. M.] and Otolaryngology [W. B. A.], Chao Family Comprehensive Cancer Center, University of California at Irvine, Orange, California 92868

The protease catalyzing the hydrolysis of the tripeptide fluorescence substrate, butoxycarbonyl-valine-proline-arginine-(7-amino-4-methylcoumarin) (Boc-Val-Pro-Arg-MCA) and the neu oncogenic protein are potentially useful biomarkers for human cancer prevention studies. In the present study, we standardized a specific substrate hydrolysis method for measuring this protease activity in human oral mucosal cells and characterized the relationship between neu oncogene expression and protease activity in patients enrolled in an oral cancer prevention trial using Bowman Birk Inhibitor Concentrate (BBIC) as the cancer preventive agent. The results demonstrate that changes in the protease activity in oral mucosal cells after BBIC treatment correlated with the changes in the neu protein levels in oral mucosal cells (r = 0.726, P < 0.001) and serum (r = 0.675, P < 0.001), suggesting that the Boc-Val-Pro-Arg-MCA hydrolyzing activity can be as useful as neu oncogene expression as a cancer biomarker. In the 25 patients enrolled in the study, the level of neu protein in oral mucosal cells correlated with the serum neu protein concentration in the patients before BBIC treatment (r = 0.645, P < 0.001). However, such a correlation was not observed after the BBIC treatment, suggesting that BBI may inhibit serine protease(s) involved in the cleavage of neu protein on the cell surface, thereby preventing the release of the extracellular domain of neu protein into the circulation. By inhibiting the cleavage of neu protein on the cell surface, BBI could prevent malignant and premalignant cells expressing high levels of neu protein antigen from escaping host immunological surveillance control.

This article has been cited by other articles:

				S. Arbogast, J. Smith, Y. Matuszczak, B. J. Hardin, J. S. Moylan, J. D. Smith, J. Ware, A. R. Kennedy, and M. B. Reid Bowman-Birk inhibitor concentrate prevents atrophy, weakness, and oxidative stress in soleus muscle of hindlimb-unloaded mice J Appl Physiol, March 1, 2007; 102(3): 956 - 964. [Abstract] [Full Text] [PDF]

				F. L. Meyskens Jr. American Society of Preventive Oncology Distinguished Career Achievement Lecture 2006--Enjoy the Journey: The Long and Winding Road of Chemoprevention Agent Development. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2038 - 2041. [Full Text] [PDF]

				C. A. Morris, L. D. Morris, A. R. Kennedy, and H. L. Sweeney Attenuation of skeletal muscle atrophy via protease inhibition J Appl Physiol, November 1, 2005; 99(5): 1719 - 1727. [Abstract] [Full Text] [PDF]

				F. L. MEYSKENS JR. Development of Bowman-Birk Inhibitor for Chemoprevention of Oral Head and Neck Cancer Ann. N.Y. Acad. Sci., December 1, 2001; 952(1): 116 - 123. [Abstract] [Full Text] [PDF]

				W. B. Armstrong, A. R. Kennedy, X. S. Wan, T. H. Taylor, Q. A. Nguyen, J. Jensen, W. Thompson, W. Lagerberg, and F. L. Meyskens Jr. Clinical Modulation of Oral Leukoplakia and Protease Activity by Bowman-Birk Inhibitor Concentrate in a Phase IIa Chemoprevention Trial Clin. Cancer Res., December 1, 2000; 6(12): 4684 - 4691. [Abstract] [Full Text]

				W. B. Armstrong, A. R. Kennedy, X. S. Wan, J. Atiba, C. E. McLaren, and F. L. Meyskens Jr. Single-Dose Administration of Bowman-Birk Inhibitor Concentrate in Patients with Oral Leukoplakia Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 43 - 47. [Abstract] [Full Text]